Milestone Pharmaceuticals Inc (MIST)

$1.55 -0.03 (-1.90%)
Market Cap 84.47M
Revenue (ttm) 0.00
Net Income (ttm) -41.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 723,900
Avg Vol 1,535,446
Day's Range N/A - N/A
Shares Out 53.46M
Stochastic %K 53%
Beta 0.96
Analysts Sell
Price Target $3.33

Company Profile

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collabora...

Industry: Biotechnology
Sector: Healthcare
Phone: 514-336-0444
Address:
1111 Dr. Frederik-Philips Boulevard, Suite 420, Montreal, Canada
NVDAMillionaire
NVDAMillionaire Jul. 28 at 8:35 PM
$MIST Brilliant piece that captures MIST's situation perfectly. So if you want to update your understanding of MIST or get to know MIST better, this is essential reading. https://beyondspx.com/article/milestone-pharmaceuticals-awaiting-the-cardamyst-verdict-nasdaq-mist
0 · Reply
Diverstj981
Diverstj981 Jul. 28 at 5:04 PM
$MIST Investors have obviously lost confidence in the management team. This company is a pure amateur hour shit-show. It's sad because there's so much potential. These clowns just fail repeatedly to execute.
0 · Reply
Bearssuckbutt
Bearssuckbutt Jul. 28 at 5:03 PM
$MIST $10 after approval! i have seen $OCGN $SMMT got from single digits to double digits in matter of weeks! buy buy buy!!
1 · Reply
Rroper
Rroper Jul. 28 at 3:42 PM
$MIST Price down shorts. I want this cheaper. Paytience
0 · Reply
Bearssuckbutt
Bearssuckbutt Jul. 28 at 3:23 PM
$MIST maybe we need a pump like $CELC and $CEAD
0 · Reply
jjangles123
jjangles123 Jul. 28 at 11:16 AM
$MIST 1.75$ end of this week
1 · Reply
Bearssuckbutt
Bearssuckbutt Jul. 27 at 6:15 PM
$MIST some facts to grind on- -More than 454,000 hospitalizations with AFib as the primary diagnosis happen each year with over 158k deaths - estimated 2.7 to 6.1 million people in the US are affected by AFIB -estimated cost to healthcare at $26 billion -If Cardamyst can address symptoms and reduce the burden to health care, this will be in fact a default therapy to treat the symptoms and reduce ER visits. - Come Dec and anticipted PDUFA approval, this will be most anticipated therapy on the market! wont be surprised if it gets scooped up $15+ by $BMY $OCGN $SMMT $DRUG
0 · Reply
Bearssuckbutt
Bearssuckbutt Jul. 27 at 5:32 PM
$MIST some facts to grind on- -More than 454,000 hospitalizations with AFib as the primary diagnosis happen each year with over 158k deaths - estimated 2.7 to 6.1 million people in the US are affected by AFIB -estimated cost to healthcare at $26 billion -If Cardamyst can address symptoms and reduce the burden to health care, this will be in fact a default therapy to treat the symptoms and reduce ER visits. - Come Dec and anticipted PDUFA approval, this will be most anticipated therapy on the market! wont be surprised if it gets scooped up $15+ by $BMY do your own research $SRPT $NVAX $VERU
0 · Reply
chezki
chezki Jul. 27 at 3:32 PM
$MIST LIKE THIS!
0 · Reply
chezki
chezki Jul. 27 at 3:29 PM
$MIST DO NOT GET TIRED!! LETS HOLD IT TOGETHER!
0 · Reply
Latest News on MIST
Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution

Jul 18, 2025, 2:16 PM EDT - 10 days ago

Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution

Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge

Jul 11, 2025, 2:37 PM EDT - 17 days ago

Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge

Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants

Jul 11, 2025, 9:30 AM EDT - 17 days ago

Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants

Milestone Pharmaceuticals Announces Proposed Public Offering

Jul 11, 2025, 6:01 AM EDT - 17 days ago

Milestone Pharmaceuticals Announces Proposed Public Offering

Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray

Jul 11, 2025, 6:00 AM EDT - 17 days ago

Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray

Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst

Jul 7, 2025, 10:01 AM EDT - 21 days ago

Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst

Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting

Jun 16, 2025, 8:00 AM EDT - 6 weeks ago

Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting

Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 2 months ago

Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

May 14, 2025, 7:04 AM EDT - 2 months ago

Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Stock Picks From Seeking Alpha's March 2025 New Analysts

Apr 4, 2025, 2:30 PM EDT - 4 months ago

Stock Picks From Seeking Alpha's March 2025 New Analysts

AI ARGX CCL CEPU CF CROX CUK

Milestone Pharmaceuticals Shares Hit New Low After FDA Rejects Etripamil

Mar 28, 2025, 10:24 AM EDT - 4 months ago

Milestone Pharmaceuticals Shares Hit New Low After FDA Rejects Etripamil

US FDA declines to approve Milestone Pharma's heart rhythm nasal spray

Mar 28, 2025, 7:06 AM EDT - 4 months ago

US FDA declines to approve Milestone Pharma's heart rhythm nasal spray

FDA Issues Complete Response Letter for Etripamil for PSVT

Mar 28, 2025, 7:00 AM EDT - 4 months ago

FDA Issues Complete Response Letter for Etripamil for PSVT

Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers

Mar 21, 2025, 3:18 PM EDT - 4 months ago

Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers

Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology

Mar 20, 2025, 8:00 AM EDT - 4 months ago

Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update

Mar 13, 2025, 7:08 AM EDT - 4 months ago

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 4, 2025, 8:00 AM EST - 5 months ago

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Feb 27, 2025, 8:00 AM EST - 5 months ago

Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil

Feb 19, 2025, 8:00 AM EST - 5 months ago

Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil

Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025

Feb 11, 2025, 8:00 AM EST - 5 months ago

Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025

Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC

Jan 28, 2025, 8:00 AM EST - 6 months ago

Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Nov 12, 2024, 9:03 AM EST - 9 months ago

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China

Sep 6, 2024, 7:00 AM EDT - 11 months ago

Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

Sep 4, 2024, 8:00 AM EDT - 11 months ago

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Aug 8, 2024, 4:17 PM EDT - 1 year ago

Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Milestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024

Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference

May 31, 2024, 8:00 AM EDT - 1 year ago

Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference

Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™

May 29, 2024, 7:00 AM EDT - 1 year ago

Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™

Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

May 13, 2024, 7:15 AM EDT - 1 year ago

Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium

Apr 17, 2024, 8:00 AM EDT - 1 year ago

Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium

Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

Apr 8, 2024, 11:36 AM EDT - 1 year ago

Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update

Mar 21, 2024, 7:14 AM EDT - 1 year ago

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update

Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference

Feb 29, 2024, 4:01 PM EST - 1 year ago

Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference

Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants

Feb 29, 2024, 7:00 AM EST - 1 year ago

Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants

Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

Feb 28, 2024, 4:37 PM EST - 1 year ago

Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January - Corcept Therapeutics (NASDAQ:CORT), Kintara Therapeutics (NASDAQ:KTRA)

Jan 2, 2024, 7:06 AM EST - 1 year ago

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January - Corcept Therapeutics (NASDAQ:CORT), Kintara Therapeutics (NASDAQ:KTRA)

CORT RPID

Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT

Dec 26, 2023, 7:00 AM EST - 1 year ago

Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT

Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

Nov 21, 2023, 7:00 AM EST - 1 year ago

Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates

Nov 13, 2023, 6:57 AM EST - 1 year ago

Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates

Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023

Nov 11, 2023, 10:00 AM EST - 1 year ago

Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023

Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR

Nov 7, 2023, 7:00 AM EST - 1 year ago

Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR

Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil

Oct 24, 2023, 7:00 AM EDT - 1 year ago

Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil

Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023

Sep 27, 2023, 7:00 AM EDT - 1 year ago

Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023

Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 5, 2023, 7:00 AM EDT - 2 years ago

Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update

Aug 10, 2023, 7:35 AM EDT - 2 years ago

Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update

Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet

Jun 20, 2023, 7:00 AM EDT - 2 years ago

Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet

Milestone Pharmaceuticals to Present at the Jefferies Healthcare Conference

Jun 1, 2023, 7:00 AM EDT - 2 years ago

Milestone Pharmaceuticals to Present at the Jefferies Healthcare Conference

Milestone Pharmaceuticals: Worthy Of A Dart Throw

May 22, 2023, 2:37 PM EDT - 2 years ago

Milestone Pharmaceuticals: Worthy Of A Dart Throw

NVDAMillionaire
NVDAMillionaire Jul. 28 at 8:35 PM
$MIST Brilliant piece that captures MIST's situation perfectly. So if you want to update your understanding of MIST or get to know MIST better, this is essential reading. https://beyondspx.com/article/milestone-pharmaceuticals-awaiting-the-cardamyst-verdict-nasdaq-mist
0 · Reply
Diverstj981
Diverstj981 Jul. 28 at 5:04 PM
$MIST Investors have obviously lost confidence in the management team. This company is a pure amateur hour shit-show. It's sad because there's so much potential. These clowns just fail repeatedly to execute.
0 · Reply
Bearssuckbutt
Bearssuckbutt Jul. 28 at 5:03 PM
$MIST $10 after approval! i have seen $OCGN $SMMT got from single digits to double digits in matter of weeks! buy buy buy!!
1 · Reply
Rroper
Rroper Jul. 28 at 3:42 PM
$MIST Price down shorts. I want this cheaper. Paytience
0 · Reply
Bearssuckbutt
Bearssuckbutt Jul. 28 at 3:23 PM
$MIST maybe we need a pump like $CELC and $CEAD
0 · Reply
jjangles123
jjangles123 Jul. 28 at 11:16 AM
$MIST 1.75$ end of this week
1 · Reply
Bearssuckbutt
Bearssuckbutt Jul. 27 at 6:15 PM
$MIST some facts to grind on- -More than 454,000 hospitalizations with AFib as the primary diagnosis happen each year with over 158k deaths - estimated 2.7 to 6.1 million people in the US are affected by AFIB -estimated cost to healthcare at $26 billion -If Cardamyst can address symptoms and reduce the burden to health care, this will be in fact a default therapy to treat the symptoms and reduce ER visits. - Come Dec and anticipted PDUFA approval, this will be most anticipated therapy on the market! wont be surprised if it gets scooped up $15+ by $BMY $OCGN $SMMT $DRUG
0 · Reply
Bearssuckbutt
Bearssuckbutt Jul. 27 at 5:32 PM
$MIST some facts to grind on- -More than 454,000 hospitalizations with AFib as the primary diagnosis happen each year with over 158k deaths - estimated 2.7 to 6.1 million people in the US are affected by AFIB -estimated cost to healthcare at $26 billion -If Cardamyst can address symptoms and reduce the burden to health care, this will be in fact a default therapy to treat the symptoms and reduce ER visits. - Come Dec and anticipted PDUFA approval, this will be most anticipated therapy on the market! wont be surprised if it gets scooped up $15+ by $BMY do your own research $SRPT $NVAX $VERU
0 · Reply
chezki
chezki Jul. 27 at 3:32 PM
$MIST LIKE THIS!
0 · Reply
chezki
chezki Jul. 27 at 3:29 PM
$MIST DO NOT GET TIRED!! LETS HOLD IT TOGETHER!
0 · Reply
Bearssuckbutt
Bearssuckbutt Jul. 27 at 2:38 AM
$MIST Kind of ironic read an article that AFIB has increased and on the rise since 2021! would that be thanks to $PFE and $MRNA maybe after all Cardamyst will be the answer to that jab! https://www.healthcentral.com/condition/atrial-fibrillation/why-are-afib-rates-on-the-rise
1 · Reply
BinaryLogic
BinaryLogic Jul. 26 at 1:57 AM
$SCNX $ALT $EBS $MIST $NVAX
2 · Reply
jjangles123
jjangles123 Jul. 25 at 11:33 PM
$MIST I like how I put my case all in one post but my guy had to spread it out. The loudest in the room is also quite often the weakest.
1 · Reply
TheGreedyGrench
TheGreedyGrench Jul. 25 at 10:39 PM
$MIST Dumping after hours. What do the institutions know that retail MIST bag holders do not??
1 · Reply
TheGreedyGrench
TheGreedyGrench Jul. 25 at 10:38 PM
$MIST Would the Grench recommend investing your money into the MIST??? NOPE!
0 · Reply
TheGreedyGrench
TheGreedyGrench Jul. 25 at 10:38 PM
$MIST BEAR Case: 6 Institutional Selling / Insider Activity Major holders like Millennium Management LLC have recently trimmed their positions, reducing institutional ownership slightly potentially signaling waning confidence at the margins
0 · Reply
TheGreedyGrench
TheGreedyGrench Jul. 25 at 10:37 PM
$MIST BEAR Case: 5 this one is my favorite and see this stock going to 0 Valuation & Speculative Profile MIST has no revenue, negative free cash flow, and a very low market cap (~$40 M–$125 M depending on source) This makes it highly speculative, with most upside tied to the success of a single FDA decision
1 · Reply
TheGreedyGrench
TheGreedyGrench Jul. 25 at 10:36 PM
$MIST BEAR Case: 4 Negative Momentum in Technicals Technical analysis shows bearish sentiment: the current price (~$0.75) is below key moving averages (20‑, 50‑, 200‑day), even as momentum indicators like RSI are low but not oversold suggesting limited technical support for a bounce
0 · Reply
TheGreedyGrench
TheGreedyGrench Jul. 25 at 10:36 PM
$MIST BEAR Case: 3 Financial Strain & Cash Burn As of March 31, 2025, cash reserves stand at $56 million, down from $69.7 million at year-end 2024, while net loss for Q1 2025 doubled to –$20.8 million year-over-year The company continues to burn cash, and upcoming milestones (e.g. FDA decision, product launch) hinge on securing further financing, posing execution and liquidity risk
0 · Reply
TheGreedyGrench
TheGreedyGrench Jul. 25 at 10:34 PM
$MIST BEAR Case: 2 MIST announced a proposed public offering (common stock and warrants) in early July 2025. Investors reacted with a ~32% share price drop due to dilution concerns and lack of clarity over pricing and size
0 · Reply
TheGreedyGrench
TheGreedyGrench Jul. 25 at 10:33 PM
$MIST BEAR Case: 1 The FDA issued a Complete Response Letter (CRL) for the lead drug CARDAMYST™ (etripamil) due to Chemistry, Manufacturing, and Controls (CMC) concerns—specifically, issues with nitrosamine impurities and a required inspection of a facility that changed ownership during review These regulatory hurdles delayed the FDA approval timeline by about a year, pushing back a previously expected March 2025 decision and resetting expectations toward December 13, 2025
0 · Reply
jjangles123
jjangles123 Jul. 25 at 9:29 PM
$MIST BULL Case: 1. Resolved CRL, the only issue was CMC/Manufacturing issues, not the efficacy of the safety or efficacy. 2. Institutional Validity, Trail’s Edge recently purchased 9.9% of the OS. 1.50$ range is a good entry. 3. Recent dilution/offering is priced in. Sharp drop from 2.5$ to 1.5$ after the news dropped. So the bad news is over. I believe it’s a climb to PDUFA day in December.
0 · Reply